Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (Q36305422)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial |
scientific article |
Statements
1 reference
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (English)
1 reference
1 reference
1 reference
Bryan Williams
1 reference
Steve Morant
1 reference
David J Webb
1 reference
Peter Sever
1 reference
Gordon McInnes
1 reference
Ian Ford
1 reference
J Kennedy Cruickshank
1 reference
Jackie Salsbury
1 reference
Morris J Brown
1 reference
British Hypertension Society's PATHWAY Studies Group
1 reference
18 September 2015
1 reference
1 reference
Identifiers
1 reference